Top Story

Cobimetinib plus vemurafenib extended PFS in BRAF V600-mutated metastatic melanoma

September 29, 2014

The addition of cobimetinib to vemurafenib significantly prolonged PFS yet increased toxicity among patients with BRAF V600-mutated melanoma, according to phase 3 study results presented at the European Society of Medical Oncology Annual Congress in Madrid.

Antoni Ribas, MD, PhD, professor of medicine at the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues evaluated data from 495 patients with unresectable locally advanced or metastatic BRAF V600-mutated melanoma. All patients were previously untreated.

Proposition 46 under fire: Experts call for better approach to physician drug testing

September 29, 2014
In two editorials published in the Annals of Internal Medicine, three physicians are speaking out against California’s Proposition 46, which would require…
Meeting News Coverage

Safety, efficacy of sorafenib exposure inconsistent in HCC, RCC patients

September 29, 2014
There was no apparent relationship between exposure to sorafenib and safety and efficacy among patients with hepatocellular carcinoma or renal cell carcinoma, according…
Meeting News Coverage

Patients with advanced pancreatic NET achieved 44-month OS with Afinitor

September 29, 2014
Results from a phase 3 trial presented at the European Society for Medical Oncology 2014 Congress in Madrid showed overall survival of more than 3.5 years in patients…
More News Headlines »
Cover Story
figure

Genomic navigators key to proper interpretation of sequencing data

HemOnc Today, August 10, 2014
Dramatic advances in the quest to identify genetic mutations that drive cancer growth have provided the scientific…
More »
Meeting News Coverage Video
figure

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »